

- Clostridium difficile*–associated disease (Cont.):
 etiology of, 857–858
 fulminant, 861
 global considerations in, 859
 health care–associated, 266, 913, 917
 pathogenesis of, 858–859, 858f
 PPIs and, 858, 1921
 prevention and control of, 861, 913, 946
 prognosis of, 861
 recurrent, 860–861
 in transplant recipient, 919, 920t, 924t
 treatment of, 86e-10, 859–860, 860t
- Clostridium* spp. infections
 bacteremia, 992, 1100
 cardiac, 1561
 enteric, 991
 epidemiology of, 990
 global considerations in, 990
 vs. IBD, 1956
 polymicrobial infections involving, 990–991, 991t
 skin and soft tissue, 992. *See also* Gas gangrene (clostridial myonecrosis)
 surgical-site, 915
 treatment of, 991t
- Clostridium perfringens* infections
 bacteremia, 992
 in cancer patient, 490
 clinical features of, 266t
 food-borne, 856, 856t, 991
 gas gangrene. *See* Gas gangrene (clostridial myonecrosis)
 necrotizing enterocolitis, 991
 necrotizing fasciitis, 783. *See also* Necrotizing fasciitis
- Clostridium septicum* infections
 bacteremia, 992
 gas gangrene. *See* Gas gangrene (clostridial myonecrosis)
 intraabdominal, 1099
 toxins in, 993
- Clostridium sordellii* infections, 782, 831, 994–995
- Clostridium tertium* infections, 992, 994
- Clostridium tetani*, 984–985. *See also* Tetanus
- Clotrimazole, 233, 349, 873t, 875
- Clotting factors. *See also* specific factors
 defective, 367
 laboratory evaluation of, 733f
 in normal hemostasis, 401, 401f
 specific factor assays, 406
- Cloxacillin, 937t
- Clozapine
 adverse effects of, 2617, 2721, 2722, 2722t
 overdose/poisoning with, 473e-9t, 2764t
 for psychosis in Huntington's disease, 2622
 for psychosis in PD, 2617
 for schizophrenia, 2721, 2722t
 therapeutic monitoring of, 2764t
- CLRs (C-type lectin receptors), 372e-5t
- Clubbing, of digits, **250**
 in cardiovascular disease, 1443, 2245
 disorders associated with, 250, 2245, 2245t
 in Graves' disease, 2295, 2295f
 in hypertrophic osteoarthropathy, 250, 426e-7, 2244, 2244f, 2245
 in lung cancer, 246, 511
 in patent ductus arteriosus, 1524f
 in respiratory disease, 47e-3, 1662
 in thyroid disease, 2245
- "Club drugs," 469e-5
- Clue cells, 873, 874, 875f
- Cluster headache, **2594**
 clinical features of, 2594–2595, 2595t
 imaging in, 2590f
 incidence of, 107t
 prevention of, 2595–2596, 2595t
 treatment of, 2595, 2595t
- Cluster of differentiation (CD) classification, 372e-1, 372e-3–4t
- Cluster-tic, 2646
- Clutton's joints, 836, 1137
- CMDs (congenital muscular dystrophies), 462e-9, 462e-10t
- CML. *See* Chronic myeloid leukemia (CML)
- CMML (chronic myelomonocytic leukemia), 102e-3, 135e-5t, 135e-6, 669
- CMR. *See* Cardiac magnetic resonance imaging (CMR)
- CMS (congenital myasthenic syndromes), 2702, 2703t
- CMT disease. *See* Charcot-Marie-Tooth (CMT) disease
- CMV. *See* Cytomegalovirus (CMV)
- CMV infections. *See* Cytomegalovirus (CMV) infections
- CMX-001 (brincidofovir), 215e-7, 261e-6
- c-myc* gene, 706
- cMYC* gene mutations, 101e-2t, 2305t
- Cnidae (cnidocyst) envenomation, 2738–2739
- CNS. *See* Central nervous system (CNS)
- Co-activators, 428
- Coagulase-negative staphylococci (CoNS), 954, 960, 961. *See also* Staphylococcal infections
- Coagulation
 fibrin clot formation in, 401, 401f
 platelet plug formation in, 400–401, 725
 in sepsis/septic shock, 1753
 in shock, 1746
- Coagulation cascade
 extrinsic pathway, 401, 733f
 intrinsic pathway, 401, 401f, 733f
 overview, 744f
 overview of, 743–744
 red blood cells fate in, 661f
- Coagulation disorders, **732**
 acquired factor inhibitors and, 740
 atherosclerosis and, 291e-8–9
 in chronic kidney disease, 1818
 in cirrhosis, 2067
 disseminated intravascular coagulation. *See* Disseminated intravascular coagulation (DIC)
 familial multiple coagulation deficiencies, 736
 genetic characteristics of, 733t
 in heatstroke, 479e-4
 hemophilia. *See* Hemophilia
 in hypothermia, 478e-2
 laboratory evaluation of, 733f, 733t, 2754–2756t
 in liver failure, 739, 739t
 in vitamin K deficiency. *See* Vitamin K deficiency
- Coagulation factor(s)
 in hepatobiliary diseases, 1998, 1998t
 multiple deficiencies of, 736
 in sepsis/septic shock, 1753
 vitamin K–dependent, 736, 736f
- Coagulation factor inhibitors, 732, 734–735, 740
- Coagulation tests, 405–406, 406t, 2754–2756t
- Coal dust, 1688t
- Coal tar, 354t
- Coal worker's pneumoconiosis, 1690
- Coarctation of the aorta, **1525**, 1620
- Coats' disease, 462e-11
- Cobalamin (vitamin B₁₂), **640**
 absorption of, 350e-1, 640, 645
 deficiency of. *See* Cobalamin (vitamin B₁₂) deficiency
 dietary sources of, 640, 644
 folate and, 641
 functions of, 96e-2f, 640
 for hypogammaglobulinemia, 375e-2
 malabsorption of, 216, 350e-1, 350e-1t, 644–645
 metabolism of, disorders of, 646
 parenteral requirement for, 98e-5t
 postgastroectomy levels of, 1927
 reference range for, 2766t
 requirement/recommended intake of, 95e-2t, 640
 serum, 647
 structure of, 96e-2f
 transport in blood, 640
- Cobalamin (vitamin B₁₂) deficiency. *See also* Megaloblastic anemia
 bacterial overgrowth syndromes in, 1944.
See also Bacterial overgrowth syndromes
 clinical features of, 96e-1t, 360, 463t, 642–643, 2607
 anemia, 398
 cardiovascular, 290e-2, 643
 dementia, 2607
 frontal lobe syndrome, 184
 gait disorders, 163
 myelopathy, 2607, 2659
 neuropathies in, 2690
 olfactory dysfunction, 216
 optic neuropathy, 203
 peripheral neuropathy, 643
 in *D. latum* infections, 1434
 diagnosis of, 647, 2690
 etiology of, 644–646, 644t, 2607, 2689–2690
 hematologic findings in, 81e-3f, 643–644, 644f
 in HIV infection, 1262
 in infants, 644, 646
 postgastroectomy, 645
 PPIs and, 568
 in pregnancy, 642
 risk factors for, 96e-1t
 small-intestinal mucosal biopsies in, 1940t
 treatment of, 648, 2607, 2690
- Cobalt exposure, 263e-3t, 472e-3, 1691
- Cobblestone papillae, 199
- Cobras, 2734, 2738. *See also* Snakebites
- Cocaine, **469e-1**
 action and effects of, 444e-4, 465e-5t, 469e-1
 adverse effects of, **469e-1**
 autonomic overactivity, 2643
 cardiomyopathy, 1562
 erectile dysfunction, 327t
 hypertension, 1617t
 intracranial hemorrhage, 2568, 2584
 myopathy, 462e-20, 462e-20t, 2218t
 nasal and auricular, 2184, 2204
 palpitations, 254
 vasculitis, 2218t
 overdose and abuse of
 clinical features of, 473e-3, 473e-8t, 473e-13t
 laboratory evaluation of, 2764t
 prevalence of, 469e-1
 treatment of, 469e-2, 473e-8t, 473e-13t
- Coccidioides* spp., 1329–1330, 1334, 1335f, 1336
- Coccidioides* spp. infections, **1334**
 arthritis, 836
 chronic meningitis, 441e-7f, 908t
 clinical features of, 1335–1336, 1336t
 complications of, 1336
 diagnosis of, 765t, 1336
 disseminated, 1335–1336
 epidemiology of, 1334–1335
 in HIV infection, 1252t, 1255
 pathogenesis of, 1335
 prevention of, 1337
 skin manifestations of, 366, 829, 1335
 subacute meningitis, 898–899
 treatment of, 1336–1337, 1336t
- Cochlea, 217, 218f
- Cochlear implant, 219, 223–224, 224f
- Cochrane Collaboration Complementary Medicine Reviews, 14e-4t
- Cochrane Database of Systematic Reviews, 25, 25t
- Cockayne syndrome, 94e-4
- Cockcroft-Gault equation, 291
- Codeine
 for diarrhea, 272
 drug interactions of, 2711t
 for dyspnea, 62t
 genetic variations in response to, 39t, 40
 metabolism of, 34t, 35
 for pain, 60, 91t
- Codman's triangle, 119e-3
- Codons, 426
- Coenurosis, 1435
- Coenzyme Q10, 2610, 2766t